We would love to hear your thoughts about our site and services, please take our survey here.
Financial year end for Sareum is end of June, last year we had a trading update end of May. Still nothing to report apart from a tweet of how well BMS are pushing ahead with their TYK2.
John has been at the Jak development forum but not presenting, just attending. Time for them to show their hand this month.
Ahfam, the 2 patents below have both been terminated before grant.
Use this link to confirm with the application number: https://www.ipo.gov.uk/p-ipsum.htm
28 November 2018
(Journal 6758) GB1816369.1 Applicant: Sareum Limited
Title: Pharmaceutical compounds
Date Lodged: 8 October 2018
20 May 2020
(Journal 6835) GB2005114.0 Applicant: Sareum Limited
Title: Crystalline Forms of a Pharmaceutical Compound
Date Lodged: 7 April 2020
Had a refresh of our CHK1 molecule and it looks like the industry is still producing research based on utilizing a CHK1 inhibitor:
https://www.sciencedaily.com/releases/2022/04/220407101045.htm
"Their findings present the biological and therapeutic relevance of Chk1 inhibition in targeting DDR and genomic instability, both of which are characteristic traits of high-risk patients with co-occurrence of the two chromosomal abnormalities. More importantly, discovering the Achilles' heel of this disease has opened doors for more effective and novel treatment modalities to address an unmet medical need of myeloma."
They used AZD7762 for the above but this is no longer in development by Astra; "Unfortunately, the clinical development of AZD7762 was hampered by drug-related cardiac toxicity, which was dose limiting in some cases"
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/prexasertib
WEE1 with CHK1: A long time link here and further evidence of this combo:
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off
Prexasertib the last remaining competitor in CHK1 discontinued in 2019:
https://www.fiercebiotech.com/biotech/lilly-dumps-phase-2-cancer-drugs-survived-previous-cull
So that leaves our molecule, previously named CCT245737, now named SRA737 as the only remaining CHK1 still active (until we are told otherwise).
The target is good but compounds mentioned above aren't safe enough to proceed to a P3 trial, I think we'll see more trials with our CHK1 and hopefully we are good enough to stay the course. Then it's a monopoly with our CHK1.
So we are betting on the skills of Sareum and ICR in molecule design, so far so good.
No, if it wasn't us it would be someone else. Competition is good, if nobody else was looking at this target then you would be worried.
You also want more treatments, which is what it is all about at the end of the day, some will be better than others in different disease and as time goes by a favourite will emerge but we're getting ahead of ourselves.
The £40k late reported trade explains the drop, mugged right off. Strange.
Come on Celtic you can piece that one together, In September we may have a fully FDA approved TYK2 in the market. Will it come with black box warnings.. hopefully not. This lays the foundation for other tyk2 compounds, none of which differentiate except Sareums.
Big JAK conference in June which a FDA rep is attending and giving speech on what they want to see. Thankfully John Reader is heading over to Boston for this.
Tim just told us and other people looking at Sareum what the market size is. BMS will be approved IMO and if you've not got a TYK2 in your arsenal as a big pharma then they've not been paying attention.
https://news.bms.com/news/details/2021/Bristol-Myers-Squibbs-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency/default.aspx
Huge date for your diary. Will a licensor wait for this date, I think not, license of SDC-1801 done by September, IMO.
Some confusion here SCH. It's not JAK2, that's what everyone wants to avoid, it's a TYK2 only.
SDC-1801 is a selective tyk2/JAK1.
JAK1 is a proven target, tyk2 is becoming another proven target, big date in September for BMS.
Been completed for a while, Tim did make a comment at the time. Payment is on any other trial first dose.
P3 fasttrack is possible with anogential .
https://www.biospace.com/article/-sareum-notes-key-takeaways-from-sierra-oncology-webcast-discussing-positive-preliminary-results-from-phase-1-2-trials-with-sra737-presented-at-asco/
"A very promising signal was observed in anogenital cancer, which represents a tractable opportunity to potentially pursue trials leading to market registration filings given its unmet medical need, particularly in patients for whom initial 1st-line therapy has become ineffective, and substantial potential market opportunity"
"To evaluate further the clinical data in the context of its emerging pipeline, noting that a Phase 2 registration trial for SRA737+LDG in anogenital cancer would cost an estimated $10 million"
GSK probably spend $10million on stationery
Quote from event organiser, "It will be a pre recorded presentation that can be found on the digital platform" https://biotrinityonline.com/
Unfortunately you need to be registered to see them. We'll have to wait on Sareum to publish this.
Now, the positive spin - if we wanted investors then 100% we would have been in person presenting, as we have done in previous years.
I don't like this at all, something not right here. They only just updated the events section a few days ago after I emailed Tim directly, they are slow to update it each year but April....
Now an RNS to say we are presenting when according to BioTrinity we aren't, a late addition - why? Someone backed out, unlikely as you book these months in advance normally to get a discount.
I just hope it is not a monumental f up.
Also the fact that the RNS states "updates", so something new is about to come out?
Who knows, but something is not right with this.
Sareum have the quietest year I can recall when looking at their event schedule. One new event, which is a good to see:
https://jak-drugdevelopment.com/program/full-event-guide/
Just shows the interest as they have their own conference for JAKi now.
Hopefully we'll be in the clinic by June.
Sareum market cap is £177m, pipeline below:
http://www.sareum.com/discovery/overview/
We are now in bed with a global pharma for CHK1, which has already completed 2 x P2 trials. 27.5% share and double digit royalties.
We have a differentiated TYK2 compound, years in development which is about to go to a P1 SAD MAD trial.
Now compare this with a TYK2 allosteric competitor,
https://ventyxbio.com/pipeline/
Went public last year, spent 2 years in development for their allosteric TYK2, readout for P1 Q3. Can't target JAK1 at all. Can't see how it will be better than other tyk2 allosterics.
Market cap converted to £, £624m. They have a strong cash position of £222m.
So based on this do you think we are under or overvalued? My opinion, definitely under valued as it is now. Once we get the CTA and II then 3bags as they say should be coming our way. Expedited CHK1 to a fasttrack application add another 3bags to start with. Buyout from this level, 10bags, the magic billion valuation. Easily achieved. Would I vote for it, yes. Then invest in the company that bought these compounds with some of the proceeds. Remember just because you sold out Sareum doesn't mean you can't keep a vested interest in what they have done for the last 20years. Multiple slices of the pie. Just hope that that one day I don't need one of there products.
https://endpts.com/crowded-rheumatoid-arthritis-category-gets-jak-reality-check-while-tnf-stalwarts-continue-to-dominate-study/
The players of the JAK class are now feeling it in the pocket, a next generation inhibitor with lower toxicity to ease the FDA concerns is needed, once this gets the PI done then all bets are off for the amount of interest from the names in that article. Hold onto these, please. Trade if you want but accumulate at every opportunity. This is a once in a lifetime opportunity and market conditions are aligning as if by magic, sometimes it's just meant to be.
As Thoth States, we can call the shots on this and multiple license per indication is not off the table. We are currently a passenger but the driving seat awaits.
A quick safety study is required here. But the amount of time and consulting is making it difficult to guess what is going on behind the scenes.
How many here have heard of ProNAI.. now in a year the same cycle will repeat and Sierra name turns into Glaxo. Sareum now having a 27.5% stake in a Glaxo compound which is more than likely going to get a blockbuster status and fasttrack unmet medical need route is what we should have had all along.
If Sareum have had kept this and done a P2 themselves it just shows the success you can have with more data. We would expect that GSK remove Sareum from their equation, because why not when you have unlimited funds and activist investors wanting to make sure of maximum returns.
With our own investors and institutions approaching this small cap can turn into something huge with the right, expanded board. Tyk2 is a pipeline in a product without a doubt.
Look at the history of Celgene https://www.fool.com/investing/2017/04/14/celgene-stock-history-the-biotechs-path-to-giganti.aspx
With the right people onboard this can be our future.
Best thing to do here is just wait this out, look at the rise to 9p+, plenty huge intraday swings in that as I remember. Maybe down a few percent today but this GSK buyout of Sierra is great news for us.
Yes you could have sold at £3.40 and bought back today but this only gives you (most of us) false confidence and you then miss the life changers or call it wrong then wait to get back in, which never comes.
Wait for the buyout then buy shares in the licensor, maybe GSK and take the dividends. Life changed.
Share trading can then be a hobby.